MLTX - MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst | Benzinga
MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week results, in which the primary endpoint was met with 29 percentage points delta versus placebo at week 12.
The data showed that the maintenance treatment with its Nanobody sonelokimab led to further improvements in HiSCR75 response rates and other clinically relevant outcomes.
The 24-week results show that ongoing treatment with sonelokimab 120mg and ...